Celera: A Biotech That Needs a Boost
The onetime genomics highflier has to replace departed founder Craig Venter and ramp up its drug-development unit -- fast
By David Shook
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.